Diplomat Pharmacy (DPLO) Receives Daily Media Impact Score of 0.14

Cornelia Mascio
Novembre 15, 2017

ProShare Advisors LLC bought a new stake in shares of Diplomat Pharmacy during the second quarter worth about $224,000. BlackRock Inc. lifted its position in shares of Diplomat Pharmacy by 158,977.3% during the 1st quarter. During the same period in the previous year, the business posted $0.21 earnings per share. analysts predict that Diplomat Pharmacy will post 0.85 EPS for the current fiscal year. Vanguard Group Inc. lifted its position in shares of Diplomat Pharmacy by 5.4% during the 2nd quarter. BlackRock Inc. now owns 6,912 shares of the company's stock worth $242,000 after buying an additional 4,405 shares during the last quarter. The firm's quarterly revenue was down 4.8% compared to the same quarter a year ago. Municipal Employees Retirement System of MI lifted its holdings in Diplomat Pharmacy by 4.9% during the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company's stock worth $127,000 after buying an additional 3,833 shares during the period. Hedge funds and other institutional investors own 76.51% of the company's stock. Evercore Wealth Mngmt Limited has 0% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 172 shares. About shares traded. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 40.48% since November 14, 2016 and is downtrending.

Traders are feeling more bullish on shares of the company lately if you put credence in the motion in short interest. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $21.99.

The P/E ratio is 168.31 and the market cap of the company is 1.34B. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34.

Analysts await Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings on February, 27. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.15 by $0.10. The firm earned $1.09 billion during the quarter, compared to analysts' expectations of $1.12 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. Diplomat Pharmacy's quarterly revenue was up 34.8% compared to the same quarter a year ago.

Diplomat Pharmacy, Inc. (Diplomat), launched on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers.

A number of brokerages recently issued reports on DPLO. Robert W. Baird restated a "buy" rating and set a $20.00 price target on shares of Diplomat Pharmacy in a research note on Sunday, September 17th. BidaskClub raised shares of Diplomat Pharmacy from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 5th. Leerink Swann boosted their target price on shares of Diplomat Pharmacy from $36.00 to $38.00 and gave the company an "outperform" rating in a research note on Wednesday, August 10th. October 4 investment analysts at Needham & Company LLC left the stock rating at "Buy" targeting a price of $23.75. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Mizuho set a $16.00 target price on shares of Diplomat Pharmacy and gave the stock a "hold" rating in a research note on Tuesday, October 24th.

Estabrook Capital Management decreased Peoples United Financial (PBCT) stake by 0.32% reported in 2017Q2 SEC filing. LLC Has $83.61 Million Stake in Diplomat Pharmacy, Inc. "(DPLO)" was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and reposted in violation of U.S. and worldwide copyright law. Its specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS). The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE